Yahoo Finance Bio-Techne Corporation Just Recorded A 7.6% EPS Beat: Here's What Analysts Are Forecasting Next
Bio-Techne Corporation (NASDAQ:TECH) defied analyst predictions to release its quarterly results, which were ahead of market expectations. The company beat expectations with revenues of US$303m arriving 3.6% ahead of forecasts. Statutory earnings per share (EPS) were US$0.31, 7.6% ahead of estimates. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.
View our latest analysis for Bio-Techne
After the latest results, the twelve analysts covering Bio-Techne are now predicting revenues of US$1.25b in 2025. If met, this would reflect a solid 8.2% improvement in revenue compared to the last 12 months. Per-share earnings are expected to accumulate 8.1% to US$1.40. Yet prior to the latest earnings, the analysts had been anticipated revenues of US$1.25b and earnings per share (EPS) of US$1.42 in 2025. The consensus analysts don't seem to have seen anything in these results that would have changed their view on the business, given there's been no major change to their estimates.
The analysts reconfirmed their price target of US$83.64, showing that the business is executing well and in line with expectations. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. The most optimistic Bio-Techne analyst has a price target of US$95.00 per share, while the most pessimistic values it at US$65.00. These price targets show that analysts do have some differing views on the business, but the estimates do not vary enough to suggest to us that some are betting on wild success or utter failure.
Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. We would highlight that Bio-Techne's revenue growth is expected to slow, with the forecast 6.5% annualised growth rate until the end of 2025 being well below the historical 12% p.a. growth over the last five years. Compare this to the 61 other companies in this industry with analyst coverage, which are forecast to grow their revenue at 6.5% per year. Factoring in the forecast slowdown in growth, it looks like Bio-Techne is forecast to grow at about the same rate as the wider industry.
The Bottom Line
The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. They also reconfirmed their revenue estimates, with the company predicted to grow at about the same rate as the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.
With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have forecasts for Bio-Techne going out to 2026, and you can see them free on our platform here.
However, before you get too enthused, we've discovered 2 warning signs for Bio-Techne that you should be aware of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
